Project Grant K01CA317043
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $190K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
- The National Cancer Institute awarded The Regents Of The University Of Colorado (University of Colorado-Denver) $706,866 on July 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to optimize FLT3-targeted and menin-modulated chimeric antigen receptor (CAR) T cell immunotherapies against KMT2A-rearranged B-cell acute lymphoblastic leukemia (ALL) and prevent treatment-resistant relapse and lineage switch to acute myeloid leukemia. The recipient will develop best-in-class...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Regents of the University of Colorado a $656,046 Project Grant on August 1, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a randomized controlled trial of EASE (Exposure-based Anxiety and Symptom Elimination), a novel behavioral intervention designed to reduce fear of cancer progression (FOP) and cancer-related trauma symptoms in adults with advanced cancer. The five-year...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of Colorado (University of Colorado-Denver) $168,691 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to refine, augment, and pilot test an affect-based physical activity promotion program for cancer survivors at elevated risk of cardiovascular disease. The award funds a K01 Career Development Award with a five-year period of performance through July 31, 2031. Work is...
- The National Cancer Institute awarded The Regents of the University of Colorado $770,666 on March 19, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate splicing-mediated dysregulation of interferon signaling in cancer. The research explores how transposons become incorporated into messenger RNAs through a process called exonization, creating altered protein isoforms. The project focuses on an exonized version of the IFNAR2 gene, which produces a receptor essential...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $156,000 to The Regents of the University of Colorado (University of Colorado-Denver) on April 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to optimize pre-clinical models of adamantinomatous craniopharyngioma. The award funds refinement of patient-derived organoid and patient-derived xenograft models derived from the recipient's tissue resource. These...
- Federal Grant Award Summary The University of Colorado-Denver received a $547,080 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on September 17, 2025, with an ultimate completion date of August 31, 2029. This award supports the University of Colorado Cancer Center's (UCCC) initiative to advance cancer screening and prevention trials through enhanced clinical trial accrual and increased diversity in participant enrollment....
- The National Cancer Institute awarded the University of Wisconsin–Madison $689,340 on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to define symptom trajectories and develop risk-stratified symptom management approaches for children with advanced cancer. The project addresses symptom burden in children aged 8–18 with metastatic, relapsed, progressed, or refractory cancer undergoing conventional and novel therapeutics. The research will characterize...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded The Regents of the University of Colorado, doing business as University of Colorado-Denver, a $625,470 Cooperative Agreement (U01CA296659) under the Cancer Biology Research program (CFDA 93.396) on May 1, 2026. The award funds research investigating the role of dietary n-3 polyunsaturated fatty acids (PUFAs) in endocrine therapy resistance (ETR) in estrogen receptor-positive breast cancer. The project...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of Colorado (University of Colorado-Denver) $163,285 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support a five-year career development project studying the intersection of cardiovascular disease and cancer. The award funds research investigating how colon cancer mediates arterial remodeling through smooth muscle cell phenotypic changes via PDGFR-B signaling. The project...
- The National Cancer Institute awarded The Regents Of The University Of Colorado (University of Colorado-Denver) $417,074 on July 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate estrogen receptor co-regulator complexes as a therapeutic target in lobular breast cancer. The research addresses why invasive lobular carcinomas (ILCs), the most common special histopathological subtype of breast cancer, show worse long-term outcomes than invasive ductal carcinomas...